| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US7192938 | HOFFMANN LA ROCHE | Method of treatment using bisphosphonic acid |
May, 2023
(4 months ago) | |
| US7718634 | HOFFMANN LA ROCHE | Method of treatment using bisphosphonic acid |
May, 2023
(4 months ago) | |
| US7410957 | HOFFMANN LA ROCHE | Method of treatment using bisphosphonic acid |
May, 2023
(4 months ago) | |
Boniva is owned by Hoffmann La Roche.
Boniva contains Ibandronate Sodium.
Boniva has a total of 3 drug patents out of which 3 drug patents have expired.
Expired drug patents of Boniva are:
- US7192938
- US7718634
- US7410957
Boniva was authorised for market use on 16 May, 2003.
Boniva is available in tablet;oral dosage forms.
Boniva can be used as treatment and prevention of osteoporosis in postmenopausal women by once-monthly oral administration of ibandronate sodium monohydrate equivalent to 150mg of ibandronic acid, treatment and prevention of osteoporosis.
The generics of Boniva are possible to be released after 06 May, 2023.
Drugs and Companies using IBANDRONATE SODIUM ingredient
Market Authorisation Date: 16 May, 2003
Treatment: Treatment and prevention of osteoporosis in postmenopausal women by once-monthly oral administration of ibandronate sodium monohydrate equivalent to 150mg of ibandronic acid; Treatment and prevention ...
Dosage: TABLET;ORAL
BONIVA family patents
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic